Furthermore, it has been clearly established that germline p53 variants are frequent in familial cancer syndromes, such as LFS or in families with hereditary breast and ovarian cancer, and surveillance of individuals with an identified germline TP53 mutation is highly beneficial to improve the likelihood of early tumor detection and subsequently improved outcomes. This evidence concerns the gene TP53 and ovarian cancer.